Individuals with Metabolic Syndrome show altered fecal lipidomic profiles with no signs of intestinal inflammation or increased intestinal permeability: a pilot study

Mia J. Coleman^{1,6}, Luis M. Espino^{1,6}, Hernan Lebensohn^{1,6}, Marija V. Zimkute^{2,6}, Negar Yaghooti³, Christina L. Ling³, Jessica M. Gross², Natalia Listwan², Sandra Cano², Vanessa Garcia², Debbie M. Lovato², Susan L. Tigert², Drew Jones⁴, Rama R. Gullapalli⁵, Neal E. Rakov³, Euriko G. Torrazza Perez³, and *Eliseo F. Castillo^{2,3}

¹ University of New Mexico School of Medicine Medical School, Albuquerque, NM 87131, USA

² Clinical and Translational Science Center, University of New Mexico Health Sciences, Albuquerque, NM 87131

³ Division of Gastroenterology and Hepatology, Department of Internal Medicine,

University of New Mexico School of Medicine, Albuquerque, NM 87131

⁴ Metabolomics Core Resource Laboratory, New York University Langone Health, New York, NY 10016

⁵ Department of Pathology, University of New Mexico Health Sciences, Albuquerque, NM 87131.

⁶ Authors contributed equally to this study

*Correspondence

Email: ecastillo@salud.unm.edu

1 University of New Mexico Division of Gastroenterology and Hepatology Department of Internal Medicine University of New Mexico Health Sciences Center Albuquerque, NM 87131, USA. 505-272-5703

Short title: Altered fecal lipidome in Metabolic Syndrome Keywords: Metabolic Syndrome, Metabolomics, Lipidomics, Dyslipidemia

ABSTRACT

Metabolic Syndrome (MetS) is a clinical diagnosis where patients exhibit three out of the five risk factors: hypertriglyceridemia, low HDL cholesterol, hyperglycemia, hypertension or increased abdominal obesity. MetS arises due to dysregulated metabolic pathways that culminate with insulin resistance and put individuals at risk to develop various comorbidities with far-reaching medical consequences such as non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease. As it stands, the exact pathogenesis of MetS as well as the involvement of the gastrointestinal tract in MetS is not fully understood. Our study aimed to evaluate intestinal health in human subjects with MetS with the goal to evaluate for any signs of underlying gut inflammation, increased intestinal permeability, and alterations in host-microbiota metabolism as assessed by fecal metabolites. No signs of intestinal inflammation or increased intestinal permeability were observed in MetS group compared to our control group. However, we found a significant increase in 417 lipid features of the gut lipidome in our MetS cohort. An identified fecal lipid, diacyl-glycerophosphocholine, showed a strong correlation with several MetS risk factors. An although our MetS cohort showed no signs of intestinal inflammation they presented with increased levels of serum TNFα that also correlated with increasing triglyceride and fecal diacyl-glycerophosphocholine levels, and decreasing HDL cholesterol levels. Taken together, our main results show MetS subjects show major alterations in fecal lipid profiles suggesting alterations in intestinal host-microbiota metabolism that may arise before concrete signs of gut inflammation or intestinal permeability become apparent. Lastly, we posit fecal metabolomics could serve as a non-invasive, accurate screening method for both MetS and NAFLD.

INTRODUCTION

The global incidence of Metabolic Syndrome (MetS), affecting over 25% of the global population (~1.97 billion) and 33% of those living in the United States, has severe health and economic consequences (1-3). MetS is comprised of multiple dysregulated metabolic pathways that can cause or result in insulin resistance (4). Current diagnostic criteria for MetS must include three out of the five risk factors: hypertriglyceridemia, low HDL cholesterol, hyperglycemia, hypertension (HTN) or increased abdominal obesity

(5). MetS is useful in detecting patients at high risk for other metabolic diseases including cardiovascular disease (CVD) (6, 7), type 2 diabetes (T2D) (8), and even hepatocellular carcinoma (HCC) (9, 10).

The liver plays a central role in the pathogenesis of MetS. Glucose and triglycerides (TG) are produced in the liver. When the liver is insulin resistant, the "brakes" on glucose and TG production are lost (11). Hypertriglyceridemia, high levels of TG, causes hepatic fat accumulation and organ dysfunction, further contributing to hepatic insulin resistance (12). Excessive fat in the liver unrelated to alcohol use, viral infections or drugs has been termed Non-Alcoholic Fatty Liver Disease (NAFLD) (13). Similar to MetS, over a billion people worldwide are affected by NAFLD (14). NAFLD is also increasingly diagnosed in children (15). This is alarming given the trajectory of disease burden in children can be decades longer than patients who develop NAFLD later in life. In the United States, health care costs directly related to NAFLD are estimated to be \$100 billion annually (15). NAFLD provides a pathophysiological "timeline" of hepatic pathology. This begins with fat accumulation (steatosis), fat accumulation with inflammation (non-alcoholic steatohepatitis, NASH) and the possibility of subsequent progression to liver cirrhosis and HCC (9). However, unlike MetS, NAFLD has specific histopathologic markers. Steatosis is defined as 5-10% of hepatocytes being fatty and steatohepatitis often exhibits ballooning necrosis, inflammation, and fibrosis (16). Although NAFLD is clinically less ambiguous to diagnose than metabolic syndrome, a biopsy is currently required to diagnose NAFLD and NASH. MetS is defined in many ways by various organizations, making it somewhat amorphous. Nevertheless, due to their closely overlapping mechanisms, NAFLD and MetS can initiate each other and predict the same disease likelihood in high-risk patients (17). While not all patients inevitably acquire comorbid metabolic derangements, cirrhosis, or malignancy; many do, warranting early intervention and clear diagnostic criteria.

Evidence suggests the gastrointestinal (GI) tract may play a significant role in metabolic diseases (18). There is a tripartite interaction in the GI tract in which the gut microbiota, the immune system, and the intestinal epithelium maintains the balance between intestinal homeostasis and inflammation (19, 20). Dysfunction in one of these

components can have profound effects on the other two systems and contributes to metabolic dysfunction (18, 21). Interestingly, gut dysbiosis and increased intestinal permeability have been observed in individuals with NAFLD and in animal models of NAFLD, suggesting a role for the GI tract in the etiology of NAFLD (22-42). Dysbiosis is also associated with obesity and T2D morbidity and disease course; influencing inflammation, gut permeability, immune function, insulin resistance, and lipid metabolism (43-47). Given the reciprocal gut-liver interaction, examining the GI tract in MetS patients could prove beneficial in both interventional strategies and preventative diagnostics.

The purpose of our pilot study was to determine if human subjects with MetS have intestinal inflammation and increased intestinal permeability similar to other metabolic diseases. Additionally, we sought to examine fecal metabolites associated with our clinical phenotype and to further understand metabolic variation as well as interactions between the gut microbiota-host. Our data indicated there is a noticeable difference in fecal lipidomics and some had a strong correlation with both increasing triglyceride and fasting insulin levels. However, there was not a significant difference in intestinal permeability or inflammation between MetS subjects and controls, suggesting metabolic perturbations may arise before gut inflammation and intestinal permeability.

METHODS

ETHICS APPROVAL AND CONSENT TO PARTICIPATE.

UNM HSC Institutional Review Boards is the Human Research Review Board (HRRC). The study "Targeting the Gastrointestinal tract in Metabolic Syndrome: proof of concept" study ID 20-170 was approved by the HRRC on 5/5/2020 with an effective date of 5/22/2020. 20-170 was approved which required consent form and HIPAA authorization signed and on record. Informed consent and HIPAA authorization waived for screening and recruitment. The University of New Mexico Health Sciences Center (UNM HSC) holds a Federal Wide Assurance (FWA) approved by the Department of Health and Human Services (HSS), FWA #00003255. This FWA is current until March 26, 2026. Under this agreement, UNM HSC assures that all of its activities related to human subjects research will be guided by The Belmont Report, a statement of principles

governing the institution in the discharge of its responsibilities for protecting the rights and welfare of human subjects of research conducted at or sponsored by the institution and conducted in accordance with all applicable regulations (e.g., 45 CFR 46, 21 CFR 50, 21 CFR 56, 21 CFR 312, 21 CFR 812). Additionally, the Institution assures that whenever it engages in research to which this Assurances applies, it will comply with the <u>http://www.hhs.gov/ohrp/assurances/assurances/filasurt.html</u>.

PARTICIPANTS

Inclusion criteria for MetS participants consisted of individuals between the ages of 30-60 years with at least three of the five risk factors of MetS. The risk factors included i) abdominal obesity: waist circumference \geq 102 cm in men or \geq 88 cm in women; ii) elevated triglycerides: \geq 150 mg/dL, or drug treatment for high triglycerides; iii) low HDL-Cholesterol: < 40 mg/dL in men or < 50 mg/dL in women, or drug treatment for low HDL-Cholesterol; iv) elevated blood pressure: Systolic \geq 130 mm Hg and/or diastolic \geq 85 mm Hg, or drug treatment for hypertension; and v) elevated fasting plasma glucose: \geq 100 mg/dL, or drug treatment for elevated glucose. Inclusion criteria for the control group consisted of individuals aged 30-60 years that did not have MetS. Exclusion criteria for both groups included individuals who have been previously diagnosed with inflammatory bowel disease, diabetes, severe hepatic dysfunction, pregnant females, lactating/breastfeeding individuals, currently on nonsteroidal anti-inflammatory drugs (NSAIDs), protein pump inhibitors, ongoing alcohol or substance abuse using AUDIT questionnaire to determine whether the participant's behaviors were suggestive of alcohol abuse, or inability to render informed consent.

STUDY DESIGN

Consented participants were instructed to visit the Clinical and Translational Science Center (CTSC) clinic after an overnight fast or a minimum of 8-hours of fasting. Blood was drawn to determine fasting glucose and insulin levels, high-sensitivity C-reactive protein (hs-CRP) levels, comprehensive metabolic panel (CMP), and lipid (triglycerides, total cholesterol, HDL and LDL cholesterol) profiles (TriCore Reference Laboratories). Additionally, Hemoglobin A1C (HbA1C) (Siemens DCA System) and tumor necrosis

factor-alpha (TNFα) (R&D Systems) were also analyzed (CTSC). Participants' height, weight, waist, waist-to-hip ratio, and body composition via bioelectrical impedance were recorded. Participants were instructed to collect 10 grams of stool for metabolomics (PRECISION™ Stool Collection System, Covidien) and fecal calprotectin. For calprotectin assay, stool was collected in a Calprotectin ELISA Stool Sample Collection Kit and ran on the corresponding ELISA kit (Eagle BioSciences, Inc).

INTESTINAL PERMEABILITY ASSAY

Within two weeks after the initial visit, participants visited the CTSC clinic after fasting overnight and provided a pre-test urine sample. Participants then ingested 50 milliliters of solution containing 5 grams of lactulose and 2 grams of D-mannitol followed immediately by 200 milliliters of water. After 3 hours, participants provided a post-test urine sample. The levels of lactulose, D-mannitol, and lactulose-mannitol ratios were assessed in the urine via ELISA (Megazyme F-FRUGL, Megazyme E-MNHPF)(48-50).

FECAL METABOLOMICS

The collected 10 grams of stool (PRECISIONTM Stool Collection System, Covidien) were sent to NYU Langone Metabolomics Core Resource Laboratory to examine fecal metabolites and lipids. Hybrid metabolomics was performed examining a standard panel of ~150 polar metabolites covering much of central carbon metabolism, and other common metabolites of interest. Separation and identification was carried out with HILIC chromatography and a library of *m*/*z* and retention times adapted from the Whitehead Institute (51), and verified with authentic standards and/or high resolution MS/MS spectral manually curated against the NIST14MS/MS and METLIN (2017) tandem mass spectral libraries (51, 52).

Global lipidomics analyses were performed to profile changes in polar lipids in a datadependent fashion. Samples were subjected to an LCMS analysis to detect and identify phospholipid molecules and quantify the relative levels of identified lipids. A lipid extraction was carried out on each sample based on published methods (53, 54). The dried samples were resolubilized in 10 μ L of a 4:3:1 mixture

(isopropanol:acetonitrile:water) and analyzed by UPLC-MS/MS with a polarity switching method modified (53, 54). The LC column was a Waters[™] CSH-C18 (2.1 x100 mm, 1.7 µm) coupled to a Dionex Ultimate 3000[™] system and the column oven temperature was set to 55°C for the gradient elution. The flow rate of 0.3 mL/min was used with the following buffers; A) 60:40 acetonitrile:water, 10 mM ammonium formate, 0.1% formic acid and B) 90:10 isopropanol:acetonitrile, 10 mM ammonium formate, 0.1% formic acid. The gradient profile was as follows; 40-43%B (0-1.25 min), 43-50%B (1.25-2 min), 50-54%B (2-11 min), 54-70%B (11-12 min), 70-99%B (12-18 min), 70-99%B (18-32min), 99-40%B (23-24 min), hold 40%B (1 min). Injection volume was set to 1 µL for all analyses (25 min total run time per injection). MS analyses were carried out by coupling the LC system to a Thermo Q Exactive HFTM mass spectrometer operating in heated electrospray ionization mode (HESI). Method duration was 20 min with a polarity switching data-dependent Top 10 method for both positive and negative modes. Spray voltage for both positive and negative modes was 3.5kV and capillary temperature was set to 320°C with a sheath gas rate of 35, aux gas of 10, and max spray current of 100 µA. The full MS scan for both polarities utilized 120,000 resolution with an AGC target of 3e6 and a maximum IT of 100 ms, and the scan range was from 350-2000 m/z. Tandem MS spectra for both positive and negative mode used a resolution of 15,000, AGC target of 1e5, maximum IT of 50 ms, isolation window of 0.4 m/z, isolation offset of 0.1 m/z, fixed first mass of 50 m/z, and 3-way multiplexed normalized collision energies (nCE) of 10, 35, 80. The minimum AGC target was 5e4 with an intensity threshold of 1e6. All data were acquired in profile mode. The top scoring structure match for each data-dependent spectrum was returned using an in-house script for MSPepSearch x64 against the LipidBlast tandem mass spectral library of lipids (55). Putative lipids were sorted from high to low by their reverse dot scores, and duplicate structures were discarded, retaining only the top-scoring MS2 spectrum and the neutral chemical formula, detected m/z, and detected polarity (+ or -) of the putative lipid was recorded. The resulting lipids were further identified manually by searching the accurate mass data against the LIPID MAPS® Structure Database (LMSD) utilizing the observed m/z(56).

STATISTICAL ANALYSIS

Statistical analysis was performed as described in figure legends and plots generated were obtained using Prism software. Plots display median (± minimum and maximum) or mean (± SE). Pearson's Correlation Coefficient were acquired using Prism software. Fecal metabolomics data were processed as described above and analyzed by NYU Langone Metabolomics Core Resource Laboratory using their in-house analysis pipeline. Cluster analysis was performed using heatmap3 (57) package in R. Raw p-values < 0.05 were used as a significance threshold for prioritizing hits of interest. Principle component analysis was conducted in Python using the Scikit-learn, matplotlib, Numpy, and Scipy.(58-61). All other data were analyzed using two-tailed unpaired Student's t test (Prism).

RESULTS

Study design and goal of the study

In this pilot study, we sought to understand differences in gut health in individuals with metabolic syndrome (MetS) compared to non-metabolic syndrome (control) participants. Specifically, examining differences in intestinal inflammation, intestinal permeability, and fecal metabolites as an insight between diet-microbiota-host interactions. This pilot study was approved by UNM HSC HRRC (see methods) and participants were recruited to and seen at UNM CTSC clinic in a two-week period. Participants were classified as having MetS or normal based on established criteria described in methods.

Clinical and biochemical analysis of study cohort

The study population consisted of 18 individuals who were seen under fasting conditions. The demographics of the study cohort are found in Table 1. After body measurements, vital signs and blood sample analyses were taken, 10 participants were classified as controls and 8 participants as MetS. Assessment of the MetS risk factors revealed the MetS group had increased abdominal obesity (Fig. 1A) and showed signs of dyslipidemia as triglycerides were significantly higher (Fig. 1B; Supplementary Table 1) and HDL cholesterol was significantly lower (Fig. 1C; Supplementary Table 1). Bioelectrical impedance analysis further revealed the MetS group had significantly

higher fat mass with no difference in lean mass (Supplementary Fig. 1A,B). Examination of fasting glucose levels revealed no difference between both groups (Fig. 1D); however, both fasting insulin levels (Fig. 1E) and Hemoglobin A1C (HbA1C) levels (Fig. 1F) were significantly higher in the MetS group. Calculation of Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), an indicator of insulin resistance, revealed the MetS group had a higher HOMA-IR score (Supplementary Fig. 1C). The calculation of insulin sensitivity via quantitative insulin sensitivity check index (QUICKI) revealed the MetS group had a lower insulin sensitivity score (Supplementary Fig. 1D) (62-64). Together the HOMA-IR and QUICKI score suggest the MetS group showed signs of insulin resistance. Blood pressure and mean arterial pressure (MAP) trended higher in the MetS group but were not significantly different to that of controls (Figure 1G-I). Lastly, we found no significant differences in the comprehensive metabolic panel (CMP) between groups including aspartate transaminase (AST), alanine aminotransferase (ALT) or AST/ALT ratios (Supplementary Table 2). Collectively, our MetS cohort showed significant differences in abdominal obesity, dyslipidemia, and insulin resistance.

Metabolic Syndrome participants show systemic inflammation that correlates with dyslipidemia

Metabolic disorders are frequently associated with low-grade inflammation (65). The term metabolic inflammation characterizes a low-level of systemic inflammation. As such, several studies have associated these conditions with increased circulating levels of acute phase proteins and cytokines such as C-reactive protein (CRP) and TNF α , respectively. To determine the level of metabolic inflammation occurring in our two groups, we examined serum levels of both TNF α and high-sensitivity C-reactive protein (hsCRP) as proxies for metabolic inflammation (66, 67). Serum TNF α levels were found to be significantly higher in the MetS group (Fig. 2A). HsCRP levels were slightly higher in the MetS group; however, this difference was not significant (Fig. 2B). Intriguingly, there was a strong positive correlation between increasing TNF α levels and increasing triglyceride levels (r=0.7978; p=0.0177) (Fig. 2D). Rising TNF α levels also had a strong negative correlation with decreasing HDL cholesterol levels (r=-0.7094; p=0.0488) (Fig.

2E). These results are consistent with the previously reported correlation between TNFα levels and dyslipidemia (68, 69).

More recently, attention has been drawn to the GI tract as a possible etiological factor driving metabolic disorders (21, 45, 65, 70). In fact, MetS and NAFLD are frequently reported in patients with inflammatory bowel disease (IBD) (71-75). Therefore, we examined the level of intestinal inflammation through a fecal calprotectin test. This noninvasive test provides a functional quantitative measure of intestinal inflammation (76-78). Interestingly, we saw no difference in fecal calprotectin levels between the control and MetS groups (Fig. 2C). Further analysis of the GI tract revealed no significant difference in intestinal barrier permeability as the lactulose to mannitol ratio was similar between both groups (Fig. 2F), as were the overall levels of recovered urine lactulose (Fig. 2G) and mannitol (Fig. 2H). This test allows for the quantification of two non-metabolized sugar molecules (*i.e.*, lactulose and mannitol) to permeate the intestinal barrier (79). Taken together, our data suggests the MetS group has a low-level of systemic inflammation but no observable signs of intestinal inflammation or barrier dysfunction.

Metabolomics reveal altered fecal metabolites in Metabolic Syndrome participants Utilizing untargeted lipidomic analyses (53, 54), we sought to identify lipids associated with our clinical phenotype. Specifically, we analyzed fecal samples from our control and MetS groups to further characterize the GI tract. Figure 3A shows a volcano plot of all 7,453 lipid features detected. The red dots on the right represent lipids with higher levels in MetS participants, while the red dots on the left are lipids with lower levels in MetS participants. The MetS group had 417 lipid features that were significantly different from control participants (Fig. 3A). The putative identification derived from LIPID MAPS® Structure Database (LMSD) (56) utilizing observed *m/z* was determined for the top 20 lipid features that showed the highest fold change in MetS fecal samples Table 2). Out of these 20 lipids, LMSD predicted they were glycerolipids, glycerophospholipids, sphingolipids, fatty acyls, and polyketides (Fig. 3B). For brevity, we also show the 30 with the lowest p-values in Supp. Table 3 and Supp. Fig. 2A.

Among these 30 lipids, LMSD predicted that all were still glycerolipids (n=9), glycerophospholipids (n=18), and sphingolipids (n=3) (Supplementary Table 3: Supplementary Fig.2A). The lipid feature that was most significantly decreased in MetS fecal samples could not be identified by LMSD. Fecal samples were also assessed for approximately 150 polar metabolites that cover much of the central carbon metabolism pathways. The principal components analysis (PCA) plot and heatmap of metabolites revealed no overall clustering of control or MetS group-derived fecal metabolites (Supplementary Fig. 2B,C). However, the volcano plot revealed two metabolites which were significantly different between groups using the *a priori* cutoffs of $[log_2FC] \ge 2$, p<0.05 (Fig. 4A). Orotic acid was significantly higher in MetS participants, while the left side shows that Carnosine was significantly lower in MetS participants (Fig. 4A) in MetS fecal samples (Fig. 4B,C). Interestingly, carnosine is a dipeptide of βalanine and histidine, and is a normal product of the liver, while orotic acid is a key intermediate in de novo pyrimidine nucleotide synthesis (HMDB 5.0) (80). Intriguingly, 5 fecal lipids that belong to the glycerolipid, glycerophospholipids, and sphingolipids categories showed a strong positive correlation with triglyceride and fasting insulin levels (Supplementary Fig. 3; statistics shown in Supplementary Table 4). PC 12:0 20:4 (Diacylglycerophosphocholine, PCaa), a glycerophosphocholine, showed a strong positive correlation with increasing triglycerides (r=0.66; p=0.0041), serum TNF α (r=0.50; p=0.0424), and fasting insulin levels (r=0.71; p=0.0015) as well as strong negative correlation with decreasing HDL cholesterol levels (r = -0.54; p = 0.0267) (Supplementary Fig. 3). Given fecal metabolites can provide insight into host-microbiota-diet interactions, our data suggest major alterations in intestinal metabolism, in the absence of localized intestinal inflammation, in MetS subjects. Lastly, our data reveals that fecal lipids could provide insight into clinical phenotypes and could serve as an alternative noninvasive method to diagnose MetS and possibly NAFLD.

DISCUSSION

In this present study, we evaluated intestinal homeostasis in individuals with or without MetS. Interestingly, MetS participants showed no signs of intestinal inflammation or increased intestinal permeability when compared to our control group. Nonetheless, we

found major differences in the gut lipidome, specifically, an increase in various types of glycerolipids, glycerophospholipids, sphingolipids, fatty acyls, and polyketides, in our MetS cohort. One fecal lipid that was identified, a diacyl-glycerophosphocholine, was increased in our MetS cohort and showed a strong correlation with several MetS risk factors. Furthermore, we found our MetS cohort had a low-level of circulating TNF α that also correlated with increasing triglyceride and fecal diacyl-glycerophosphocholine levels as well as decreasing "good" HDL cholesterol levels. Taken together, our main results show MetS subjects show major alterations in intestinal lipid profiles suggesting alterations in intestinal host and microbiota metabolism which may precede intestinal dysfunction.

MetS and NAFLD can both predict similar diseases including T2D, CVD and NASH (81, 82). In addition, the liver is a shared focal point for both metabolic disorders as glucose and triglycerides are overproduced in the liver. The increase in triglycerides can lead to fat accumulation and is often associated with hepatic insulin resistance (12). Unfortunately, both metabolic disorders can go undiagnosed as the individual can appear asymptomatic. Given the role of the liver in these two metabolic diseases, liver enzymes (e.g., ALT, AST, ALT:AST) could provide clues to disease progression. However, we observed no differences in these liver enzymes between our study groups (Supplementary Table 2). Liver enzymes are also often normal in NAFLD patients and therefore not consistent diagnostic markers (12). The gold standard of NAFLD diagnosis relies on liver biopsy. Liver biopsy is an invasive procedure with many absolute contraindications (coagulopathies, recent NSAID use, inability to identify an appropriate biopsy site) and relative contraindications (morbid obesity, infection, ascites). A liver biopsy is also handicapped by only being able to capture pathology in a specific moment in time. NAFLD is a chronic inflammatory disease. Like many chronic inflammatory disorders, NAFLD can have a dynamic relapsing-remitting pattern (65). Over a short period of time NAFLD can oscillate between steatosis and steatohepatitis (65). Fibrosis can flare and spontaneously regress (65). Additionally, a liver biopsy cannot accurately assess a fluctuating disease process. It is therefore not appropriate to do liver biopsies on all patients with suspected NAFLD or MetS, even if a biopsy is

medically feasible (83). Safer, faster, and more accessible testing is needed. Metabolomics may offer a non-invasive, accurate method of screening for both MetS and NAFLD. Metabolomics can analyze and quantify metabolites and lipids linked to metabolic pathways and changes could offer insight into clinical phenotypes.

Mining biofluids such as plasma, serum, urine and even stool can help identify biomarkers for diseases. Unlike other biofluids, stool gives a comprehensive look into the GI tract as it contains microorganisms, microbial by-products, nutrients such as fibers and lipids, and inflammatory molecules. Thus, stool samples can provide molecular clues into GI health. For instance, bacterial fermentation of dietary fiber can generate metabolites such as short chain fatty acids (SCFAs) such butyrate, propionate and acetate that in turn modulate microbiota composition, intestinal epithelial and immune cell function, and lipid metabolism (84-91). When the production of SCFAs is decreased from dysbiosis, it can subsequently derail barrier and immune function as well as lipid metabolic pathways. Our metabolomic analyses of stool samples revealed major alterations in the gut lipidome in individuals with MetS. We observed increases in glycerophospholipids like glycerophosphocholines as well as ceramides, a type of sphingolipids. Both glycerophosphocholines and ceramides are increased in the serum of NAFLD and NASH patients (92-94). They are also strongly associated with CVD and T2D (95-99). A reduction in ceramides can improve hepatic steatosis and insulin sensitivity (100, 101). Interestingly, gut microbiota produced sphingolipids can be taken up by the intestine (102) and can enter into host metabolic pathways increasing hepatic ceramide levels (103). In addition to changes in fecal lipids, our MetS cohort also showed an increase in orotic acid, an intermediate of pyrimidine nucleotide biosynthesis, in stool samples. Similar to the lipids described above, orotic acid has also been linked to metabolic risk factors like hypertension (104) and can induce NAFLD in a various rodent models (105, 106). Carnosine, which was decreased in our MetS group, has proven beneficial in reducing abdominal obesity, blood pressure and glucose in humans and animal models (107-111). Overall, our observation of differential lipids and metabolites that associated with clinical phenotypes suggest stool samples could prove beneficial as a diagnostic or preventative biofluid for metabolic disorders.

Our goal in this pilot study was to examine GI health in individuals with MetS. This cohort showed no signs of intestinal inflammation or increase in intestinal permeability. Animal models utilizing high-fat diets (plus glucose) to induce obesity, metabolic endotoxemia, and insulin resistances show alterations in the gut microbiota (18, 21). In addition, these models have been instrumental in showing high-fat diets also cause an increase in intestinal permeability and inflammation (45, 112-115). In human subjects, intestinal inflammation has been observed in more advanced liver diseases like cirrhosis and HCC (116, 117). IBD patients also can develop MetS and NAFLD while NAFLD and NASH patients have an increased risk in developing CRC (71-75, 118-120). Targeting the GI tract with probiotics in NAFLD and NASH patients has proved beneficial in reducing liver enzymes, hepatic inflammation, hepatic steatosis, and hepatic fibrosis further supporting a role for the GI tract (121-130). Nevertheless, these studies still do not completely explain the cause of gut dysbiosis and decreased barrier function, the increased risk of IBD and CRC in NAFLD patients or how the probiotics are working. Thus, there is a critical gap in knowledge regarding how the GI tract, possibly through host-microbiota metabolic interaction, is involved in metabolic diseases. We posit our MetS cohort showed no signs of intestinal dysfunction because changes in host-microbiota metabolism precedes inflammation (131). Future endeavors to characterize gut metabolism could provide insight into the etiology of metabolic disorders like MetS and NAFLD.

DECLARATIONS

CONSENT FOR PUBLICATION: All authors consent for publication.

AVAILABILITY OF DATA AND MATERIALS: The datasets generated and analyzed during this study are not publicly available because of institutional review board restrictions, but data acquisition is described in methods.

COMPETING INTERESTS: None declared.

FUNDING: This project is supported by an award from the National Center for Advancing Translational Sciences, National Institutes of Health under grant number UL1TR001449 (E.F.C.).

AUTHOR'S CONTRIBUTION: M.J.C, L.M.E., H.L., N.Y., C.L.L. and E.F.C. designed the study. M.V.Z, N.L., S.C., V.Y.G., M.J.C, L.M.E., H.L., S.K., D.M.L., S.L.T., D.J. and E.F.C. contributed to data acquisition and patient interaction. M.J.C., L.M.E., H.L., N.Y., C.L.L., J.M.G., D.R.J., R.R.G., N.E.R., E.G.T.P, and E.F.C. analyzed, interpreted data and statistical analysis. M.J.C, L.M.E., H.L., and E.F.C. wrote the first draft of the manuscript. All authors reviewed, edited and approved the manuscript.

ACKNOWLEDGEMENTS: We would like to acknowledge Christina R. Anderson, George Garcia, Donna L. Sedillo, Morgan Wong, UNM Hospital Investigational Drug Studies team, and the CTSC T-1 laboratory. We acknowledge NYU Langone Health's Metabolomics Laboratory for its help in acquiring and analyzing the data presented.

REFERENCES

- 1. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens Rep.* 2018;20(2):12.
- 2. Vaquero Alvarez M, Aparicio-Martinez P, Fonseca Pozo FJ, Valle Alonso J, Blancas Sanchez IM, and Romero-Saldana M. A Sustainable Approach to the Metabolic Syndrome in Children and Its Economic Burden. *Int J Environ Res Public Health.* 2020;17(6).
- Scholze J, Alegria E, Ferri C, Langham S, Stevens W, Jeffries D, and Uhl-Hochgraeber K. Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. *BMC Public Health*. 2010;10(529.
- Simmons RK AK, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, Reaven G, Hama Sambo B, Mendis S, Roglic G. Diabetologia; 2010.
- 5. Eckel RH, Alberti KG, Grundy SM, and Zimmet PZ. The metabolic syndrome. *Lancet*. 2010;375(9710):181-3.
- 6. Li X, Zhai Y, Zhao J, He H, Li Y, Liu Y, Feng A, Li L, Huang T, Xu A, et al. Impact of Metabolic Syndrome and It's Components on Prognosis in Patients With Cardiovascular Diseases: A Meta-Analysis. *Front Cardiovasc Med.* 2021;8(704145.
- Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, and Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-32.
- 8. Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, Lee WC, Kang MI, Yim HW, Yoon KH, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. *J Diabetes Investig.* 2013;4(4):334-43.
- 9. Yki-Järvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). *Diabetologia*. 2016;59(6):1104-11.
- Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P, and Montella M. Metabolic syndrome and hepatocellular carcinoma risk. *Br J Cancer*. 2013;108(1):222-8.
- 11. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, and Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. *J Clin Endocrinol Metab.* 2002;87(7):3023-8.
- 12. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, and Yki-Jarvinen H. Liver fat in the metabolic syndrome. *J Clin Endocrinol Metab.* 2007;92(9):3490-7.
- 13. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, and Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*. 2012;55(6):2005-23.
- 14. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, and Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* 2018;15(1):11-20.
- 15. Eslam M, Sanyal AJ, George J, and Panel IC. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology*. 2020;158(7):1999-2014.e1.

- 16. Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ, and Force AAftSoLDNT. NAFLD: Reporting Histologic Findings in Clinical Practice. *Hepatology*. 2021;73(5):2028-38.
- 17. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *Lancet Diabetes Endocrinol.* 2014;2(11):901-10.
- 18. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, and Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes*. 2008;57(6):1470-81.
- 19. Kayama H, Okumura R, and Takeda K. Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine. *Annu Rev Immunol.* 2020;38(23-48.
- 20. Brown EM, Kenny DJ, and Xavier RJ. Gut Microbiota Regulation of T Cells During Inflammation and Autoimmunity. *Annu Rev Immunol.* 2019;37(599-624.
- 21. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes*. 2007;56(7):1761-72.
- 22. Nier A, Engstler AJ, Maier IB, and Bergheim I. Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children. *PLoS One.* 2017;12(9):e0183282.
- 23. Miele L, Giorgio V, Liguori A, Petta S, Pastorino R, Arzani D, Alberelli MA, Cefalo C, Marrone G, Biolato M, et al. Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. *Nutr Metab Cardiovasc Dis.* 2020;30(11):2103-10.
- 24. De Munck TJI, Xu P, Verwijs HJA, Masclee AAM, Jonkers D, Verbeek J, and Koek GH. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis. *Liver Int.* 2020.
- 25. Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Konigsrainer A, Maier KP, Bischoff SC, and Bergheim I. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. *J Nutr.* 2008;138(8):1452-5.
- 26. Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for nonalcoholic steatohepatitis development. *J Hepatol.* 2019;71(6):1216-28.
- 27. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Masciana R, Forgione A, Gabrieli ML, Perotti G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology*. 2009;49(6):1877-87.
- 28. Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y, Smith T, Neish AS, Li H, Tan S, et al. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. *Gastroenterology*. 2016;151(4):733-46 e12.
- 29. Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, Motola DL, Luther S, Bohr S, Jeoung SW, et al. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. *Cell Mol Gastroenterol Hepatol.* 2015;1(2):222-32.
- 30. Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, and Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. *Hepatobiliary Pancreat Dis Int.* 2017;16(4):375-81.
- 31. Panasevich MR, Meers GM, Linden MA, Booth FW, Perfield JW, 2nd, Fritsche KL, Wankhade UD, Chintapalli SV, Shankar K, Ibdah JA, et al. High-fat, high-fructose, high-cholesterol feeding causes severe NASH and cecal microbiota dysbiosis in juvenile Ossabaw swine. *Am J Physiol Endocrinol Metab.* 2018;314(1):E78-E92.

- 32. Brandl K, and Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. *Curr Opin Gastroenterol.* 2017;33(3):128-33.
- 33. Nistal E, Saenz de Miera LE, Ballesteros Pomar M, Sanchez-Campos S, Garcia-Mediavilla MV, Alvarez-Cuenllas B, Linares P, Olcoz JL, Arias-Loste MT, Garcia-Lobo JM, et al. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. *Rev Esp Enferm Dig.* 2019;111(4):275-82.
- 34. Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, and Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. *Sci Rep.* 2018;8(1):1466.
- 35. Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, Liu C, Chen YW, and Fan JG. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. *World J Gastroenterol.* 2017;23(1):60-75.
- 36. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature*. 2012;482(7384):179-85.
- 37. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, and Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. *Sci Rep.* 2015;5(8096.
- 38. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology*. 2016;63(3):764-75.
- 39. Wutthi-In M, Cheevadhanarak S, Yasom S, Kerdphoo S, Thiennimitr P, Phrommintikul A, Chattipakorn N, Kittichotirat W, and Chattipakorn S. Gut Microbiota Profiles of Treated Metabolic Syndrome Patients and their Relationship with Metabolic Health. *Sci Rep.* 2020;10(1):10085.
- 40. Org E, Blum Y, Kasela S, Mehrabian M, Kuusisto J, Kangas AJ, Soininen P, Wang Z, Ala-Korpela M, Hazen SL, et al. Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort. *Genome Biol.* 2017;18(1):70.
- 41. Lippert K, Kedenko L, Antonielli L, Kedenko I, Gemeier C, Leitner M, Kautzky-Willer A, Paulweber B, and Hackl E. Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults. *Benef Microbes.* 2017;8(4):545-56.
- 42. Kootte RS, Levin E, Salojarvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab.* 2017;26(4):611-9 e6.
- 43. McPhee JB, and Schertzer JD. Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation. *Clin Sci (Lond)*. 2015;129(12):1083-96.
- 44. Matey-Hernandez ML, Williams FMK, Potter T, Valdes AM, Spector TD, and Menni C. Genetic and microbiome influence on lipid metabolism and dyslipidemia. *Physiol Genomics*. 2018;50(2):117-26.
- 45. Luck H, Tsai S, Chung J, Clemente-Casares X, Ghazarian M, Revelo XS, Lei H, Luk CT, Shi SY, Surendra A, et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. *Cell Metab.* 2015;21(4):527-42.
- 46. Frazier TH, DiBaise JK, and McClain CJ. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. *JPEN J Parenter Enteral Nutr.* 2011;35(5 Suppl):14S-20S.

- 47. Bleau C, Karelis AD, St-Pierre DH, and Lamontagne L. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes. *Diabetes Metab Res Rev.* 2015;31(6):545-61.
- 48. Sequeira IR, Lentle RG, Kruger MC, and Hurst RD. Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability. *PLoS One.* 2014;9(6):e99256.
- 49. Kingstone K, and Gillett HR. Lactulose-mannitol intestinal permeability test: a useful screening test for adult coeliac disease. *Ann Clin Biochem.* 2001;38(Pt 4):415-6.
- 50. Dastych M, Dastych M, Jr., Novotna H, and Cihalova J. Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease. *Dig Dis Sci.* 2008;53(10):2789-92.
- 51. Chen WW, Freinkman E, Wang T, Birsoy K, and Sabatini DM. Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism. *Cell.* 2016;166(5):1324-37 e11.
- 52. Smith CA, O'Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, Custodio DE, Abagyan R, and Siuzdak G. METLIN: a metabolite mass spectral database. *Ther Drug Monit.* 2005;27(6):747-51.
- 53. Vorkas PA, Shalhoub J, Isaac G, Want EJ, Nicholson JK, Holmes E, and Davies AH. Metabolic phenotyping of atherosclerotic plaques reveals latent associations between free cholesterol and ceramide metabolism in atherogenesis. *J Proteome Res.* 2015;14(3):1389-99.
- 54. Vorkas PA, Isaac G, Anwar MA, Davies AH, Want EJ, Nicholson JK, and Holmes E. Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease. *Anal Chem.* 2015;87(8):4184-93.
- 55. Kind T, Liu KH, Lee DY, DeFelice B, Meissen JK, and Fiehn O. LipidBlast in silico tandem mass spectrometry database for lipid identification. *Nat Methods.* 2013;10(8):755-8.
- 56. Sud M, Fahy E, and Subramaniam S. Template-based combinatorial enumeration of virtual compound libraries for lipids. *J Cheminform.* 2012;4(1):23.
- 57. Zhao S, Guo Y, Sheng Q, and Shyr Y. Advanced heat map and clustering analysis using heatmap3. *Biomed Res Int.* 2014;2014(986048.
- 58. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat Methods.* 2020;17(3):261-72.
- 59. Harris CR, Millman KJ, van der Walt SJ, Gommers R, Virtanen P, Cournapeau D, Wieser E, Taylor J, Berg S, Smith NJ, et al. Array programming with NumPy. *Nature*. 2020;585(7825):357-62.
- 60. Hunter JD. Matplotlib: A 2D graphics environment. *Comput Sci Eng.* 2007;9(3):90-5.
- 61. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R, Dubourg V, et al. Scikit-learn: Machine Learning in Python. *J Mach Learn Res.* 2011;12(2825-30.
- 62. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A, Kazakos K, Yovos J, and Bakris GL. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. *J Hum Hypertens*. 2007;21(9):709-16.
- 63. Quon MJ. QUICKI is a useful and accurate index of insulin sensitivity. *J Clin Endocrinol Metab.* 2002;87(2):949-51.
- 64. Mohn A, Marcovecchio M, and Chiarelli F. Validity of HOMA-IR as index of insulin resistance in obesity. *J Pediatr.* 2006;148(4):565-6; author reply 6.
- 65. Tilg H, Zmora N, Adolph TE, and Elinav E. The intestinal microbiota fuelling metabolic inflammation. *Nature reviews Immunology*. 2020;20(1):40-54.
- 66. Bassuk SS, Rifai N, and Ridker PM. High-sensitivity C-reactive protein: clinical importance. *Curr Probl Cardiol.* 2004;29(8):439-93.

- 67. Popa C, Netea MG, van Riel PL, van der Meer JW, and Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. *J Lipid Res.* 2007;48(4):751-62.
- 68. Pauciullo P, Gentile M, Marotta G, Baiano A, Ubaldi S, Jossa F, Iannuzzo G, Faccenda F, Panico S, and Rubba P. Tumor necrosis factor-alpha is a marker of familial combined hyperlipidemia, independently of metabolic syndrome. *Metabolism.* 2008;57(4):563-8.
- 69. Grunfeld C, and Feingold KR. Tumor necrosis factor, cytokines, and the hyperlipidemia of infection. *Trends Endocrinol Metab.* 1991;2(6):213-9.
- 70. Winer DA, Winer S, Dranse HJ, and Lam TK. Immunologic impact of the intestine in metabolic disease. *J Clin Invest.* 2017;127(1):33-42.
- 71. Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, and Shen B. Risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel disease. *J Crohns Colitis*. 2013;7(8):e279-85.
- 72. Magri S, Paduano D, Chicco F, Cingolani A, Farris C, Delogu G, Tumbarello F, Lai M, Melis A, Casula L, et al. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history. *World J Gastroenterol.* 2019;25(37):5676-86.
- 73. Michalak A, Mosinska P, and Fichna J. Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives. *Pharmacol Rep.* 2016;68(4):837-46.
- 74. Dragasevic S, Stankovic B, Kotur N, Sokic-Milutinovic A, Milovanovic T, Lukic S, Milosavljevic T, Srzentic Drazilov S, Klaassen K, Pavlovic S, et al. Metabolic Syndrome in Inflammatory Bowel Disease: Association with Genetic Markers of Obesity and Inflammation. *Metab Syndr Relat Disord*. 2020;18(1):31-8.
- 75. Verdugo-Meza A, Ye J, Dadlani H, Ghosh S, and Gibson DL. Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites. *Nutrients.* 2020;12(5).
- 76. Bjarnason I. The Use of Fecal Calprotectin in Inflammatory Bowel Disease. *Gastroenterol Hepatol* (*N Y*). 2017;13(1):53-6.
- 77. Konikoff MR, and Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. *Inflamm Bowel Dis.* 2006;12(6):524-34.
- 78. Fagerberg UL, Loof L, Lindholm J, Hansson LO, and Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2007;45(4):414-20.
- 79. Vojdani A. For the assessment of intestinal permeability, size matters. *Altern Ther Health Med.* 2013;19(1):12-24.
- Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL, et al. HMDB 5.0: the Human Metabolome Database for 2022. *Nucleic Acids Res.* 2022;50(D1):D622-D31.
- 81. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. *Diabetologia*. 2010;53(4):600-5.
- 82. Anstee QM, Targher G, and Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nature reviews Gastroenterology & hepatology*. 2013;10(6):330-44.
- 83. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, American Gastroenterological A, American Association for the Study of Liver D, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology*. 2012;142(7):1592-609.

- 84. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, and Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res.* 2013;54(9):2325-40.
- 85. Allayee H, and Hazen SL. Contribution of Gut Bacteria to Lipid Levels: Another Metabolic Role for Microbes? *Circ Res.* 2015;117(9):750-4.
- 86. Suzuki T, Yoshida S, and Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. *Br J Nutr.* 2008;100(2):297-305.
- 87. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN, and Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science*. 2013;341(6145):569-73.
- 88. Yang W, Yu T, Huang X, Bilotta AJ, Xu L, Lu Y, Sun J, Pan F, Zhou J, Zhang W, et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. *Nat Commun.* 2020;11(1):4457.
- 89. Sun M, Wu W, Chen L, Yang W, Huang X, Ma C, Chen F, Xiao Y, Zhao Y, Ma C, et al. Microbiotaderived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. *Nat Commun.* 2018;9(1):3555.
- 90. Goncalves P, Araujo JR, and Di Santo JP. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2018;24(3):558-72.
- 91. Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, Wilson KE, Glover LE, Kominsky DJ, Magnuson A, et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. *Cell Host Microbe*. 2015;17(5):662-71.
- 92. Anjani K, Lhomme M, Sokolovska N, Poitou C, Aron-Wisnewsky J, Bouillot JL, Lesnik P, Bedossa P, Kontush A, Clement K, et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. *J Hepatol.* 2015;62(4):905-12.
- 93. Papandreou C, Bullo M, Tinahones FJ, Martinez-Gonzalez MA, Corella D, Fragkiadakis GA, Lopez-Miranda J, Estruch R, Fito M, and Salas-Salvado J. Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial. *Nutr Metab (Lond).* 2017;14(58.
- 94. Luukkonen PK, Zhou Y, Sadevirta S, Leivonen M, Arola J, Oresic M, Hyotylainen T, and Yki-Jarvinen H. Hepatic ceramides dissociate steatosis and insulin resistance in patients with nonalcoholic fatty liver disease. *J Hepatol.* 2016;64(5):1167-75.
- 95. Syme C, Czajkowski S, Shin J, Abrahamowicz M, Leonard G, Perron M, Richer L, Veillette S, Gaudet D, Strug L, et al. Glycerophosphocholine Metabolites and Cardiovascular Disease Risk Factors in Adolescents: A Cohort Study. *Circulation*. 2016;134(21):1629-36.
- 96. Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam KP, Milburn MV, Kastenmuller G, Adamski J, Tuomi T, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. *Diabetes*. 2013;62(5):1730-7.
- 97. Lemaitre RN, Yu C, Hoofnagle A, Hari N, Jensen PN, Fretts AM, Umans JG, Howard BV, Sitlani CM, Siscovick DS, et al. Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study. *Diabetes.* 2018;67(8):1663-72.
- 98. McGurk KA, Keavney BD, and Nicolaou A. Circulating ceramides as biomarkers of cardiovascular disease: Evidence from phenotypic and genomic studies. *Atherosclerosis.* 2021;327(18-30.
- 99. Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, Suoniemi M, Hurme R, Marz W, Scharnagl H, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. *Eur Heart J.* 2016;37(25):1967-76.

- 100. Xia JY, Holland WL, Kusminski CM, Sun K, Sharma AX, Pearson MJ, Sifuentes AJ, McDonald JG, Gordillo R, and Scherer PE. Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis. *Cell Metab.* 2015;22(2):266-78.
- 101. Chaurasia B, Tippetts TS, Mayoral Monibas R, Liu J, Li Y, Wang L, Wilkerson JL, Sweeney CR, Pereira RF, Sumida DH, et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. *Science*. 2019;365(6451):386-92.
- 102. Duan RD. Physiological functions and clinical implications of sphingolipids in the gut. *J Dig Dis.* 2011;12(2):60-70.
- 103. Johnson EL, Heaver SL, Waters JL, Kim BI, Bretin A, Goodman AL, Gewirtz AT, Worgall TS, and Ley RE. Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels. *Nat Commun.* 2020;11(1):2471.
- 104. Choi YJ, Yoon Y, Lee KY, Kang YP, Lim DK, Kwon SW, Kang KW, Lee SM, and Lee BH. Orotic acid induces hypertension associated with impaired endothelial nitric oxide synthesis. *Toxicol Sci.* 2015;144(2):307-17.
- 105. Fatty liver induction by orotic acid. *Nutr Rev.* 1960;18(339-40.
- 106. Bang WS, Hwang YR, Li Z, Lee I, and Kang HE. Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats. *J Pharm Pharm Sci.* 2019;22(1):98-111.
- 107. Al-Sawalha NA, Alshogran OY, Awawdeh MS, and Almomani BA. The effects of I-Carnosine on development of metabolic syndrome in rats. *Life Sci.* 2019;237(116905.
- 108. Nagai K, Tanida M, Niijima A, Tsuruoka N, Kiso Y, Horii Y, Shen J, and Okumura N. Role of Lcarnosine in the control of blood glucose, blood pressure, thermogenesis, and lipolysis by autonomic nerves in rats: involvement of the circadian clock and histamine. *Amino Acids*. 2012;43(1):97-109.
- 109. Anderson EJ, Vistoli G, Katunga LA, Funai K, Regazzoni L, Monroe TB, Gilardoni E, Cannizzaro L, Colzani M, De Maddis D, et al. A carnosine analog mitigates metabolic disorders of obesity by reducing carbonyl stress. *J Clin Invest*. 2018;128(12):5280-93.
- 110. Baye E, Ukropec J, de Courten MP, Vallova S, Krumpolec P, Kurdiova T, Aldini G, Ukropcova B, and de Courten B. Effect of carnosine supplementation on the plasma lipidome in overweight and obese adults: a pilot randomised controlled trial. *Sci Rep.* 2017;7(1):17458.
- 111. Lee YT, Hsu CC, Lin MH, Liu KS, and Yin MC. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. *Eur J Pharmacol.* 2005;513(1-2):145-50.
- 112. Arnone D, Vallier M, Hergalant S, Chabot C, Ndiaye NC, Moulin D, Aignatoaei AM, Alberto JM, Louis H, Boulard O, et al. Long-Term Overconsumption of Fat and Sugar Causes a Partially Reversible Pre-inflammatory Bowel Disease State. *Front Nutr.* 2021;8(758518.
- 113. Gulhane M, Murray L, Lourie R, Tong H, Sheng YH, Wang R, Kang A, Schreiber V, Wong KY, Magor G, et al. High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22. *Sci Rep.* 2016;6(28990.
- 114. Zhang X, Monnoye M, Mariadassou M, Beguet-Crespel F, Lapaque N, Heberden C, and Douard V. Glucose but Not Fructose Alters the Intestinal Paracellular Permeability in Association With Gut Inflammation and Dysbiosis in Mice. *Front Immunol.* 2021;12(742584.
- 115. Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, Braverman S, Tengeler AC, Barak O, Elazar M, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. *Science.* 2018;359(6382):1376-83.
- 116. Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, et al. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. *Hepatology*. 2019;69(1):107-20.

- 117. Gundling F, Schmidtler F, Hapfelmeier A, Schulte B, Schmidt T, Pehl C, Schepp W, and Seidl H. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. *Liver Int.* 2011;31(9):1406-15.
- 118. Lin XF, Shi KQ, You J, Liu WY, Luo YW, Wu FL, Chen YP, Wong DK, Yuen MF, and Zheng MH. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. *Mol Biol Rep.* 2014;41(5):2989-97.
- 119. Lin X, You F, Liu H, Fang Y, Jin S, and Wang Q. Site-specific risk of colorectal neoplasms in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. *PLoS One*. 2021;16(1):e0245921.
- 120. Cho Y, Lim SK, Joo SK, Jeong DH, Kim JH, Bae JM, Park JH, Chang MS, Lee DH, Jung YJ, et al. Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm. *Liver Int.* 2019;39(9):1722-31.
- 121. Xue L, He J, Gao N, Lu X, Li M, Wu X, Liu Z, Jin Y, Liu J, Xu J, et al. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. *Sci Rep.* 2017;7(45176.
- 122. Xiao MW, Lin SX, Shen ZH, Luo WW, and Wang XY. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. *Gastroenterol Res Pract.* 2019;2019(1484598.
- 123. Tang Y, Huang J, Zhang WY, Qin S, Yang YX, Ren H, Yang QB, and Hu H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. *Therap Adv Gastroenterol.* 2019;12(1756284819878046.
- 124. Qamar AA. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis. *J Clin Gastroenterol.* 2015;49 Suppl 1(S28-32.
- 125. Liu L, Li P, Liu Y, and Zhang Y. Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. *Dig Dis Sci.* 2019;64(12):3402-12.
- 126. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, and Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. *Hepatology*. 2003;37(2):343-50.
- 127. Famouri F, Shariat Z, Hashemipour M, Keikha M, and Kelishadi R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. *J Pediatr Gastroenterol Nutr.* 2017;64(3):413-7.
- 128. Endo H, Niioka M, Kobayashi N, Tanaka M, and Watanabe T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. *PLoS One.* 2013;8(5):e63388.
- 129. Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, Crawford D, Campbell C, and Vitetta L. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. *Therap Adv Gastroenterol.* 2016;9(4):463-72.
- 130. A SL, D VR, Manohar T, and A AL. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. *Euroasian J Hepatogastroenterol.* 2017;7(2):130-7.
- 131. Litvak Y, Byndloss MX, and Baumler AJ. Colonocyte metabolism shapes the gut microbiota. *Science.* 2018;362(6418).

Individuals with Metabolic Syndrome show altered fecal lipidomic profiles with no signs of intestinal inflammation or increased intestinal permeability: a pilot study

Coleman et al.,

Contents: Figures 1-4 and figure legends; Supplementary Figures 1-3 and figure legends



















Supplementary 1



Supplementary 2





Supplementary 3

	Triglycerides	HDL-Cholesterol	TNFa	Waist	Fasting Insulin	TG 12:0_12:0_22:3	LPC 0:0/20:4;O	DG 19:0_20:0	Cer 18:1;03/24:0;0	TG 19:1_22:6_22:6	PE P-16:0/16:1	DG 13:0_20:5	PC P-16:0/15:1	Cer 18:1;03/26:0;02	PC 12:0_20:4	Carnosine	Orotic Acid			1.0
Triglycerides	1.00	-0.79	0.64	0.70	0.60	0.43	0.24	0.56	0.55	0.59	0.15	0.26	0.15	0.55	0.66	-0.27	0.23			1.0
HDL-Cholesterol	-0.79	1.00	-0.55	-0.78	-0.60	-0.10	-0.25	-0.45	-0.47	-0.47	-0.23	0.04	-0.27	-0.46	-0.54	0.15	-0.14			
TNFa	0.64	-0.55	1.00	0.36	0.54	0.15	0.17	0.37	0.39	0.40	0.06	-0.02	0.05	0.38	0.50	0.17	0.20			
Waist	0.70	-0.78	0.36	1.00	0.62	0.11	0.08	0.35	0.36	0.39	0.08	0.03	0.16	0.33	0.45	-0.32	0.26			
Fasting Insulin	0.60	-0.60	0.54	0.62	1.00	-0.05	-0.15	0.63	0.74	0.78	-0.13	0.08	-0.11	0.67	0.71	-0.25	-0.03		1	0.5
TG 12:0_12:0_22:3	0.43	-0.10	0.15	0.11	-0.05	1.00	0.74	0.41	0.28	0.26	0.64	0.80	0.56	0.39	0.38	-0.23	0.65			
LPC 0:0/20:4;O	0.24	-0.25	0.17	0.08	-0.15	0.74	1.00	0.37	0.24	0.15	0.93	0.39	0.87	0.35	0.33	-0.25	0.46			
DG 19:0_20:0	0.56	-0.45	0.37	0.35	0.63	0.41	0.37	1.00	0.98	0.96	0.35	0.21	0.26	0.99	0.91	-0.26	-0.02			
Cer 18:1;O3/24:0;O	0.55	-0.47	0.39	0.36	0.74	0.28	0.24	0.98	1.00	0.99	0.23	0.17	0.15	0.99	0.92	-0.25	-0.09	-	-	0
TG 19:1_22:6_22:6	0.59	-0.47	0.40	0.39	0.78	0.26	0.15	0.96	0.99	1.00	0.14	0.18	0.07	0.97	0.92	-0.26	-0.10			
PE P-16:0/16:1	0.15	-0.23	0.06	0.08	-0.13	0.64	0.93	0.35	0.23	0.14	1.00	0.42	0.98	0.33	0.19	-0.29	0.30			
DG 13:0_20:5	0.26	0.04	-0.02	0.03	0.08	0.80	0.39	0.21	0.17	0.18	0.42	1.00	0.41	0.23	0.15	-0.20	0.57			
PC P-16:0/15:1	0.15	-0.27	0.05	0.16	-0.11	0.56	0.87	0.26	0.15	0.07	0.98	0.41	1.00	0.24	0.11	-0.33	0.30	-	-	-0.5
Cer 18:1;O3/26:0;O2	0.55	-0.46	0.38	0.33	0.67	0.39	0.35	0.99	0.99	0.97	0.33	0.23	0.24	1.00	0.92	-0.25	-0.02			
PC 12:0_20:4	0.66	-0.54	0.50	0.45	0.71	0.38	0.33	0.91	0.92	0.92	0.19	0.15	0.11	0.92	1.00	-0.27	0.12			
Carnosine	-0.27	0.15	0.17	-0.32	-0.25	-0.23	-0.25	-0.26	-0.25	-0.26	-0.29	-0.20	-0.33	-0.25	-0.27	1.00	0.08			
Orotic Acid	0.23	-0.14	0.20	0.26	-0.03	0.65	0.46	-0.02	-0.09	-0.10	0.30	0.57	0.30	-0.02	0.12	0.08	1.00			-10

Figure legends

Figure 1. Metabolic Syndrome risk factors. Clinical and biochemical analysis of healthy controls (HC) and metabolic syndrome (MetS) participants. Graph showing **(A)** abdominal obesity (*i.e.*, waist circumference); **(B)** Triglyceride levels; **(C)** HDL Cholesterol; **(D)** Fasting Glucose levels; **(E)** Fasting Insulin levels; **(F)** Hemoglobin A1c (HbA1c) levels; **(G)** Systolic blood pressure; **(H)** Diastolic blood pressure; and **(I)** Mean Arterial Pressure (MAP). Graphs indicate median (± minimum and maximum). * p<0.05, **p<0.01, and ns, not significant. Two-tailed unpaired Student's t tests.

Figure 2. Assessment of systemic and intestinal inflammatory markers. Serum and fecal levels of inflammatory markers were measured in HC and MetS participants. Plot showing (A) serum TNF α levels; (B) serum hsCRP levels; (C) Fecal Calprotectin levels. (D and E) Pearson's correlation coefficients between (D) TNF α and triglycerides and (E) TNF α and HDL Cholesterol. Plot showing (F) Lactulose/Mannitol ratio; (G) Total Lactulose levels recovered in the urine; and (H) Total Mannitol levels recovered in the urine. Plots indicate median (± minimum and maximum) or mean (± SE). * p<0.05, and ns, not significant. Two-tailed unpaired Student's t tests.

Figure 3. Untargeted lipidomics show major fecal lipid variations. (A) Volcano plot from UPLC-MS/MS-based untargeted lipidomics of stool from MetS and HC subjects (n= 7-10/group) depicting the 7,453 lipids features obtained following MS data processing. Metabolite peak intensities were extracted according to a library of m/z values and retention times developed with authentic standards. Intensities were extracted with an in-house script with a 10 ppm tolerance for the theoretical m/z of each metabolite, and a maximum 30 sec retention time window. Each dot represents one lipid, dashed lines indicate default thresholds for significance (p<0.05) and fold change up- or downregulation by 2-fold (Log2FC=1). The red dots on the right represent the lipids with higher levels in MetS participants, while the dots on the left are the lipids with lower levels in MetS with respect to HCs. **(B)** Plot showing the top 20 LMSD identified lipids with highest fold change (mean; p<0.05). GPL, glycerophosholipids; SP, sphingolipids; FA, fatty acyls.

Figure 4. Hybrid metabolomics of stool samples. (A) Volcano plot from hybrid LCMS assay of stool from MetS and HC subjects (n = 7-10/group) depicting a standard panel of approx. 150 polar metabolites. Each dot represents one metabolite, dashed lines indicate default thresholds for significance (p<0.05) and fold change up- or down-regulation by 2-fold ([Log2FC]=1). The red dot on the right represents a metabolite with higher levels in MetS participants, while the dots on the left is a metabolite with lower levels in MetS in respect to HCs. Plot showing the intensity values of fecal (**B**) Orotic acid and (**C**) Carnosine in MetS and HC participants. Plots indicate median (\pm minimum and maximum). * p<0.05. Two-tailed unpaired Student's t tests.

Supplementary Figure 1. Body Composition and Insulin resistances calculation.

Plots showing body composition between MetS and HC, **(A)** Fat mass and **(B)** Lean mass. Plot showing two indices commonly used to diagnose the insulin resistance based on fasting serum insulin and glucose. **(C)** HOMA-IR and **(D)** QUICKI. Plots indicate median (± minimum and maximum). ** p<0.01, *** p<0.001. Two-tailed unpaired Student's t tests.

Supplementary Figure 2. Fecal lipidomics. **(A)** Plot showing the top 30 LMSD identified fecal lipids found to be the most significantly different (mean; *p*-value range: 0.008 - 0.003). SP, sphingolipids. **(B)** Three component Principal components analysis (PCA) model of hybrid metabolites. Color represents sample group, please see figure legend. **(C)** Heatmap showing unsupervised clustering analysis of samples (HC vs MetS) using the significant metabolites (p<0.05) from the comparison, samples were clustered with the Complete method and Euclidian distance function.

Supplementary Figure 3. Pearson's correlation coefficients between Metabolic Syndrome risk factors and fecal metabolites. Heatmap showing Pearson's r between triglyceride, HDL cholesterol, TNF α , fasting insulin, and fecal metabolites that included the top 10 lipids identified in figure 3B, carnosine, and orotic acid. Pearson's r, 0.5 – 1 and (-0.5) – (-1) were found to be significant, p<0.05 (supplementary table 4).

Table 1. Demographics of study cohort.

Demographics		Controls	Metabolic Syndrome
Gender	Male	4	3
	Female	6	5
Age	Median	42.50	50.50
	Minimum	31	45
	Maximum	56	58
Race/Ethnicity	Non-Hispanic White	4	2
	Hispanic	6	4
	Native American		1
	Black		1

Feature	Observed	Log2 Fold	p-value	Putative ID*	Main Class (Abbrev. Chains)
5617	771.5399	4.076	0.0167	(Category) Glycerolipids	Triradylglycerols (TG 12:0 12:0 22:3)
1432	558 4388	3 477	0.0333	Glycerophospholipids	Oxid glycerophospholipids (LPC 0:0/20:4:0)
4624	665 7446	3 367	0.0256	Chycorolipide	
4031	005.7440	3.307	0.0250	Giycerolipius	
4799	680.7542	3.333	0.0325	Sphingolipids	Ceramides (Cer 18:1;O3/24:0;O)
6916	989.5998	3.326	0.0303	Glycerolipids	Triradylglycerols (TG 19:1_22:6_22:6)
4688	672.6672	3.326	0.0424	Glycerophospholipids	Glycerophosphoethanolamines (PE P-16:0/16:1)
3675	571.3263	3.261	0.0395	Fatty Acyls	Diradylglycerols (DG 13:0_20:5)
5044	700.6979	3.252	0.0229	Glycerophospholipids	Glycerophosphocholines (PC P-16:0/15:1)
5270	724.7805	3.244	0.0255	Sphingolipids	Ceramides (Cer 18:1;O3/26:0;O2)
5266	724.4458	3.231	0.0079	Glycerophospholipids	Glycerophosphocholines (PC 12:0_20:4)
6454	905.5635	3.216	0.0350	Glycerolipids	Triradylglycerols (TG 18:3_18:3_20:0)
5128	709.7706	3.201	0.0291	Glycerolipids	Diradylglycerols (DG 21:0_22:6)
5129	710.1051	3.158	0.0341	Polyketides	Flavonoids
7315	1371.8158	3.127	0.0076	Sphingolipids	Neutral glycosphingolipids (Hex(3)-HexNAc-Fuc-Cer 34:1;O2)
4442	651.0691	3.104	0.0337	Polyketides	Flavonoids
1490	531.4196	3.103	0.0159	Fatty Acyls	Fatty esters (FA 36:2)
5383	739.1213	3.094	0.0267	Polyketides	Flavonoids
4961	695.0953	3.077	0.0322	Polyketides	Flavonoids
4980	695.7639	3.059	0.0333	Fatty Acyls	Fatty amides
4982	696.0981	3.045	0.0333	Polyketides	Flavonoids

Table 2. Putative LMSD ID of lipids with the highest fold change in the MetS group.

* Putative ID derived from LIPID MAPS® Structure Database (LMSD) utilizing observed *m/z*.

Supplementary Table 1.Lipid Panel

Lipid Panel	Controls	Metabolic Syndrome	p-value
Total Cholesterol (mg/dL)	192.3 ± 28.95	174.6 ± 35.23	0.2592
HDL Cholesterol (mg/dL)	60.4 ± 12.21	44.0 ± 10.38	**0.0081
LDL Cholesterol (mg/dL)	111.9 ± 29.02	92.63 ± 34.78	0.2177
<i>Triglycerides (</i> mg/dL)	100.3 ± 49.01	190.1 ± 52.76	**0.0018

Supplementary Table 2. Comprehensive Metabolic Panel

Comprehensive Metabolic Panel	Controls	Metabolic Syndrome	p-value
Sodium (mmol/L)	139.7 ± 2.497	140.0 ± 2.268	0.7954
<i>Potassium (</i> mmol/L)	4.2 ± 0.1563	4.3 ± 0.4629	0.5923
<i>Chloride (</i> mmol/L)	108.3 ± 2.710	109.4 ± 3.739	0.9612
CO ₂ (mmol/L)	23.8 ± 2.821	24.88 ± 3.137	0.4555
Anion Gap	7.8 ± 1.398	7.6 ± 2.825	0.8655
<i>Calcium (</i> mg/dL)	9.34 ± 0.334	9.488 ± 0.554	0.4937
<i>BUN (</i> mg/dL)	13.7 ± 2.584	14.5 ± 5.398	0.6836
<i>Creatinine (</i> mg/dL)	0.83 ± 0.1642	0.93 ± 0.1864	0.2439
<i>Total Protein (</i> gm/dL)	7.33 ± 0.5478	7.5 ± 0.2928	0.4416
<i>Albumin (</i> gm/dL)	4.030 ± 0.2058	4.013 ± 0.4643	0.9158
<i>Globulin (</i> gm/dL)	3.3 ± 0.5121	3.5 ± 0.3182	0.3801
<i>Bilirubin (</i> mg/dL)	0.73 ± 0.4473	0.54 ± 0.2825	0.3063
Alk Phos (U/L)	73.40 ± 21.25	91.80 ± 20.21	0.0795
AST (U/L)	23.20 ± 10.17	24.80 ± 13.81	0.7705
ALT (U/L)	35.40 ± 14.07	48.50 ± 34.51	0.2884

Feature ID	Observed <i>m</i> /z	Log2 Fold Change	p-value	Putative ID* (Category)	Main Class
5728	785.4944	2.166	0.0031	Glycerolipids	Triacylglycerols
5013	698.4442	2.075	0.0033	Glycerophospholipids	Diacylglycerophosphocholines
2341	379.249	1.746	0.0034	Glycerophospholipids	Monoacylglycerophosphates
7313	1370.813	2.903	0.0039	Sphingolipids	Gangliosides
6227	870.5284	2.009	0.0042	Glycerophospholipids	Diacylglycerophosphocholines
6242	872.5436	2.329	0.0044	Glycerophospholipids	Diacylglycerophosphocholines
5992	828.5175	2.121	0.0044	Glycerophospholipids	Diacylglycerophosphocholines
3763	583.4164	1.548	0.0045	Glycerolipids	Diacylglycerols
5406	741.4679	2.077	0.0048	Glycerolipids	Triacylglycerols
5393	740.4648	2.040	0.0048	Glycerophospholipids	Diacylglycerophosphocholines
3496	543.3401	1.759	0.0050	Fatty Acyls	N-acyl amines
5998	829.5205	2.336	0.0050	Glycerolipids	Triacylglycerols
5717	784.4908	2.042	0.0051	Glycerophospholipids	Diacylglycerophosphocholines
6217	869.516	1.884	0.0056	Glycerolipids	Triacylglycerols
4984	696.439	1.957	0.0056	Glycerophospholipids	Diacylglycerophosphocholines
5363	736.4338	1.696	0.0060	Glycerophospholipids	Diacylglycerophosphocholines
3319	514.4841	2.231	0.0060	Glycerophospholipids	Monoacylglycerophosphocholines
5965	824.4862	1.776	0.0061	Glycerophospholipids	Diacylglycerophosphocholines
5676	780.4599	1.824	0.0062	Glycerophospholipids	Diacylglycerophosphocholines
3773	584.4232	1.202	0.0063	Sphingolipid	N-acyl-4-hydroxysphinganines
4482	654.4183	1.921	0.0063	Glycerophospholipids	Diacylglycerophosphoethanolamines
4454	652.4126	1.910	0.0064	Glycerophospholipids	Oxidized glycerophosphoserines
4998	697.4416	2.015	0.0064	Glycerolipids	Diacylglycerols
5403	741.3887	2.106	0.0067	Glycerophospholipids	Diacylglycerophosphoglycerols

Supplementary Table 3. Putative LMSD ID of the top 30 lipids with the lowest p-value.

6509	913.5423	1.983	0.0068	Glycerolipids	Triacylglycerols
4468	653.4156	1.901	0.0069	Glycerolipids	Diacylglycerols
6368	893.5571	1.889	0.0070	Glycerolipids	Triacylglycerols
6211	868.5124	1.835	0.0070	Glycerophospholipids	Diacylglycerophosphocholines
5549	761.4656	1.974	0.0072	Glycerophospholipids	Diacylglycerophosphoglycerols
3344	520.4426	1.813	0.0073	Glycerophospholipids	1-alkyl,2-acylglycerophosphocholines

* Putative ID derived from LIPID MAPS® Structure Database (LMSD) utilizing observed *m/z*.

	ΤG	HDL	TNFa	Waist	Fastin g Insulin	TG 12:0_12: 0_22:3	LPC 0:0/20: 4;O	DG 19:0_ 20:0	Cer 18:1;O3/ 24:0;O	TG 19:1_22: 6_22:6	PE P- 16:0/1 6:1	DG 13:0_ 20:5	PC P- 16:0/1 5:1	Cer 18:1;O3/2 6:0;O2	PC 12:0_ 20:4	Carn osine	Oroti c Acid
TG		0.00 0141 4	0.00 5818 1	0.00 1694 4	0.011 0971	0.0832 66	0.350 6808	0.02 0493 4	0.0208 516	0.0124 057	0.560 0992	0.30 4309 3	0.577 0568	0.02192 02	0.00 4059 4	0.29 3271 2	0.38 3246 7
HDL	0.00 0141 4		0.02 2516 1	0.00 0248 9	0.010 4991	0.7028 851	0.335 9979	0.07 1106 4	0.0541 797	0.0546 851	0.367 1168	0.89 2750 9	0.285 5902	0.06489 36	0.02 6722 5	0.56 7694 9	0.59 8806 5
TNFa	0.00 5818 1	0.02 2516 1		0.15 1756	0.024 7077	0.5745 035	0.504 3884	0.14 6262	0.1254 476	0.1102 487	0.806 539	0.93 5236 1	0.849 7161	0.13543 81	0.04 2435 4	0.51 3636 8	0.43 7062
Waist	0.00 1694 4	0.00 0248 9	0.15 1756		0.007 5049	0.6634 113	0.757 8497	0.17 0033 6	0.1542 508	0.1168 081	0.757 3819	0.90 7780 4	0.531 4953	0.19286 03	0.07 2166 3	0.20 6232 9	0.31 8706 1
Fastin g Insulin	0.01 1097 1	0.01 0499 1	0.02 4707 7	0.00 7504 9	0.055	0.8554 288	0.552 6751	0.00 6886 3	0.0006 232	0.0002	0.615	0.75 4729 1	0.670 2456	0.00317 34	0.00 1474 1	0.32 4256 8	0.92 4117 9
12:0_1 2:0_22: 3	0.08 3266	0.70 2885 1	0.57 4503 5	0.66 3411 3	0.855 4288		0.000 7066	0.10 6021 4	922	0.3148 562	0.005 9602	0.00 0106 4	0.019 4417	0.12686 71	0.13 2910 5	0.37 2925 5	0.00 4483 1
LPC 0:0/20: 4;0	0.35 0680 8	0.33 5997 9	0.50 4388 4	0.75 7849 7	0.552 6751	0.0007 066		0.14 1297	0.3572 801	0.5578 425	6.898 E-08	0.12 3396	5.888 E-06	0.16553 4	0.19 5726 5	0.32 7258 1	0.06 5903 7
DG 19:0_2 0:0	0.02 0493 4	0.07 1106 4	0.14 6262	0.17 0033 6	0.006 8863	0.1060 214	0.141 297		1.439E- 11	7.582E -10	0.164 1165	0.42 8288 6	0.307 7152	2.254E- 15	2.83 1E- 07	0.32 3137 4	0.92 7373 2
Cer 18:1;0 3/24:0; 0	0.02 0851 6	0.05 4179 7	0.12 5447 6	0.15 4250 8	0.000 6232	0.2726 922	0.357 2801	1.43 9E- 11		5.258E -15	0.374 1861	0.50 6605 6	0.559 525	2.336E- 14	1.35 3E- 07	0.33 4461 8	0.74 0269 7
TG 19:1_2 2:6_22: 6	0.01 2405 7	0.05 4685 1	0.11 0248 7	0.11 6808 1	0.000 2196	0.3148 562	0.557 8425	7.58 2E- 10	5.258E- 15		0.583 9394	0.49 7891 2	0.780 0795	5.979E- 11	1.55 7E- 07	0.31 6190 9	0.69 9724 4
PE P- 16:0/16 :1	0.56 0099 2	0.36 7116 8	0.80 6539	0.75 7381 9	0.615 2011	0.0059 602	6.898 E-08	0.16 4116 5	0.3741 861	0.5839 394		0.09 158	1.095 E-11	0.19013 25	0.45 5186 2	0.26 4724 5	0.23 6595 1
DG 13:0_2 0:5	0.30 4309 3	0.89 2750 9	0.93 5236 1	0.90 7780 4	0.754 7291	0.0001 064	0.123 396	0.42 8288 6	0.5066 056	0.4978 912	0.091 58		0.103 3159	0.37526 86	0.56 4997 6	0.43 7404 2	0.01 6723 7

Supplementary Table 4. Pearson's coefficient correlation p-value corresponding to supplementary figure 3.

PC P-	0.57	0.28	0.84	0.53	0.670	0.0194	5.888	0.30	0.5595	0.7800	1.095	0.10		0.34465	0.67	0.20	0.23
16:0/15	7056	5590	9716	1495	2456	417	E-06	7715	25	795	E-11	3315		75	7851	1643	4595
.1	8	2	1	3				2				9			1	8	3
TG	0.02	0.06	0.13	0.19	0.003	0.1268	0.165	2.25	2.336E-	5.979E	0.190	0.37	0.344		1.44	0.34	0.93
18:3_1	1920	4893	5438	2860	1734	671	534	4E-	14	-11	1325	5268	6575		E-07	1048	0070
0:3_20: 0	2	6	1	3				15				6				8	8
DG	0.00	0.02	0.04	0.07	0.001	0.1329	0.195	2.83	1.353E-	1.557E	0.455	0.56	0.677	1.44E-		0.28	0.63
21:0_2	4059	6722	2435	2166	4741	105	7265	1E-	07	-07	1862	4997	8511	07		5452	2948
2.0	4	5	4	3				07				6				1	
Carnos	0.29	0.56	0.51	0.20	0.324	0.3729	0.327	0.32	0.3344	0.3161	0.264	0.43	0.201	0.34104	0.28		0.77
ine	3271	7694	3636	6232	2568	255	2581	3137	618	909	7245	7404	6438	88	5452		4500
	2	9	8	9				4				2			1		1
Orotic	0.38	0.59	0.43	0.31	0.924	0.0044	0.065	0.92	0.7402	0.6997	0.236	0.01	0.234	0.93007	0.63	0.77	
Acid	3246	8806	7062	8706	1179	831	9037	7373	697	244	5951	6723	5953	08	2948	4500	
	7	5		1				2				7				1	